FLUDARABINE PHOSPHATE INJECTION, USP SOLUTION

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

FLUDARABINE PHOSPHATE

थमां उपलब्ध:

ACCORD HEALTHCARE INC

ए.टी.सी कोड:

L01BB05

INN (इंटरनेशनल नाम):

FLUDARABINE

डोज़:

25MG

फार्मास्यूटिकल फॉर्म:

SOLUTION

रचना:

FLUDARABINE PHOSPHATE 25MG

प्रशासन का मार्ग:

INTRAVENOUS

पैकेज में यूनिट:

2ML

प्रिस्क्रिप्शन प्रकार:

Prescription

चिकित्सीय क्षेत्र:

ANTINEOPLASTIC AGENTS

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0123842003; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2015-03-11

उत्पाद विशेषताएं

                                Page 1 of 55
PRODUCT MONOGRAPH
PR
FLUDARABINE PHOSPHATE INJECTION, USP
Fludarabine Phosphate
Sterile Solution
for Injection
25 mg/mL
(2 mL per vial)
USP
Antineoplastic
Accord Healthcare Inc.
3535 Boulevard St. Charles, Suite 704,
Kirkland, QC,
Canada, H9H 5B9
Date of Revision:
September 29, 2021
Submission
Control No: 253592
Page 2 of 55
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................3
SUMMARY PRODUCT INFORMATION
......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................3
CONTRAINDICATIONS
.................................................................................................
4
WARNINGS AND
PRECAUTIONS................................................................................
4
ADVERSE
REACTIONS..................................................................................................
9
DRUG INTERACTIONS
.................................................................................................
13
DOSAGE AND
ADMINISTRATION..............................................................................
13
OVERDOSAGE
...............................................................................................................
14
ACTION AND CLINICAL
PHARMACOLOGY............................................................
14
STORAGE AND
STABILITY..........................................................................................
16
SPECIAL HANDLING INSTRUCTIONS
......................................................................
17
DOSAGE FORMS, COMPOSITION AND
PACKAGING............................................. 17
PART II: SCIENTIFIC INFORMATION
...........................................................................
18
PHARMACEUTICAL INFORMATION
........................................................................
18
CLINICAL
TRIALS............................................................
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 29-09-2021

इस उत्पाद से संबंधित अलर्ट देखें

दस्तावेज़ इतिहास देखें